^
Association details:
Biomarker:MET overexpression
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer

Published date:
10/05/2023
Excerpt:
According to the receiver operating characteristics and Kaplan-Meier curve analyses, patients with high c-MET, EGFR, and VEGFR2 expression at baseline had significantly shorter PFS than those with low expression.
Secondary therapy:
Chemotherapy
DOI:
10.3389/fimmu.2023.1086479